Tag
Two global phase 3 trials show rocatinlimab, an anti‑OX40 therapy, produced statistically significant improvements in EASI‑75 and vIGA‑AD 0/1 at 24 weeks versus placebo with a generally acceptable safety profile.
A nationwide Taiwanese active-comparator cohort found SGLT2 inhibitor use was associated with a lower incidence of new-onset atopic dermatitis compared with DPP‑4 inhibitors; the effect persisted across sensitivity analyses, showed a dose-r
A Taiwanese nationwide cohort study found SGLT2 inhibitor use linked to a lower incidence of new-onset atopic dermatitis versus DPP4 inhibitors (IPTW-adjusted HR 0.847), with a dose-response effect and stronger protection in men.
A phase II trial evaluating rilzabrutinib, a BTK inhibitor, in moderate-to-severe atopic dermatitis showed no significant improvement in primary endpoints but demonstrated rapid itch relief and a favorable safety profile.
A large pragmatic trial demonstrates that daily emollient application starting before 9 weeks of age significantly reduces the risk of atopic dermatitis by 24 months in infants not selected for high risk, offering a feasible preventive appr
